Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Catheterization~   1. Elevated pulmonary arterial pressure (PA mean \>25mmHg)~  2. Elevated pulmonary vascular resistance (\>240 dynes.cm.sec-5) or transpulmonary gradient (\>12 mmHg)~  3. Elevated LVEDP (\>15mmHg, but ≤23 mmHg)~2. Evidence of left ventricular diastolic dysfunction: LA\>4.0, LVH or diastolic dysfunction by mitral filling pattern~3. Echocardiogram: Normal or mildly reduced LV ejection fraction (greater than or equal to 40%)~4. Symptomatic chronic HF (WHO functional class II-IV)~5. Baseline walk distance 100 to 400 meters~6. Age 18 - 80 (increased from 70)~Maximal treatment of diastolic dysfunction as noted by the treating physicians with no change in medical therapy for one month prior to entry~Exclusion Criteria:~1. Use of endothelin receptor antagonist, prostacyclin or PDE-5 inhibitor within 4 weeks of enrollment~2. Exercise capacity limited by other illness (other lung disease, arthritis, mobility limitations)~3. Uncontrolled systemic hypertension~4. Uncontrolled atrial fibrillation~5. Severe valvular disease~6. Pregnant females- females of child bearing potential will need to use contraceptive agent barrier given the teratogenicity associated with ERA's~7. Uncontrolled OSA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).